Cargando…
Infectious complications of immune checkpoint inhibitors in solid organ malignancies
BACKGROUND: Immune checkpoint inhibitors (ICIs) are targeted cancer therapies regarded to have less toxicity than chemotherapy. Immune‐related adverse events (irAEs) of ICIs are well described in the literature but limited data exist on their infectious complications. The objective is to describe th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704147/ https://www.ncbi.nlm.nih.gov/pubmed/34873868 http://dx.doi.org/10.1002/cam4.4393 |
_version_ | 1784621637390303232 |
---|---|
author | Ross, Justine Abella Komoda, Kellie Pal, Sumanta Dickter, Jana Salgia, Ravi Dadwal, Sanjeet |
author_facet | Ross, Justine Abella Komoda, Kellie Pal, Sumanta Dickter, Jana Salgia, Ravi Dadwal, Sanjeet |
author_sort | Ross, Justine Abella |
collection | PubMed |
description | BACKGROUND: Immune checkpoint inhibitors (ICIs) are targeted cancer therapies regarded to have less toxicity than chemotherapy. Immune‐related adverse events (irAEs) of ICIs are well described in the literature but limited data exist on their infectious complications. The objective is to describe the spectrum and risk factors for developing serious infections in patients receiving ICIs. METHODS: Retrospective review of patients with melanoma, renal cell carcinoma, or nonsmall‐cell lung cancer on nivolumab, pembrolizumab, and/or ipilimumab from January 1, 2017 to November 30, 2017. Exclusion: receipt of less than two ICI doses or history of other malignancy. Characteristics: age, sex, prior chemotherapy, steroid use, and temozolomide or infliximab use. Data identified from microbiology, radiography, serology, or physician note documentation. Serious infection is defined as infections requiring hospitalization and/or IV antibiotics from initiation of ICI until the end of the study period. RESULTS: One hundred and eleven pts received ICIs. Suspected or confirmed bacterial infections occurred in 24% (27/111) with 8% (9/111) confirmed bacterial cultures. The overall serious infection rate was 14% (16/111) with 25% (4/16) confirmed bacterial cultures. Suspected or confirmed infection sites: genitourinary 20% (22/111), pneumonia 5% (7/111), skin/soft tissue 7% (8/111). Noninfectious pneumonitis (NIP) occurred in 5% (5/111). No association regarding the risk of infection between the type of malignancy and ICI used. Steroid use was the only risk factor significantly associated with serious infection: 12/16 (75%) on steroids versus 27/95 (28.4%) without steroid use (p = 0.0003). CONCLUSION: The rate of serious infection with ICI was higher in our study compared with previous reports of pts treated with melanoma. Infectious complications are encountered with ICIs and correlate with steroid use. |
format | Online Article Text |
id | pubmed-8704147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87041472022-01-04 Infectious complications of immune checkpoint inhibitors in solid organ malignancies Ross, Justine Abella Komoda, Kellie Pal, Sumanta Dickter, Jana Salgia, Ravi Dadwal, Sanjeet Cancer Med Clinical Cancer Research BACKGROUND: Immune checkpoint inhibitors (ICIs) are targeted cancer therapies regarded to have less toxicity than chemotherapy. Immune‐related adverse events (irAEs) of ICIs are well described in the literature but limited data exist on their infectious complications. The objective is to describe the spectrum and risk factors for developing serious infections in patients receiving ICIs. METHODS: Retrospective review of patients with melanoma, renal cell carcinoma, or nonsmall‐cell lung cancer on nivolumab, pembrolizumab, and/or ipilimumab from January 1, 2017 to November 30, 2017. Exclusion: receipt of less than two ICI doses or history of other malignancy. Characteristics: age, sex, prior chemotherapy, steroid use, and temozolomide or infliximab use. Data identified from microbiology, radiography, serology, or physician note documentation. Serious infection is defined as infections requiring hospitalization and/or IV antibiotics from initiation of ICI until the end of the study period. RESULTS: One hundred and eleven pts received ICIs. Suspected or confirmed bacterial infections occurred in 24% (27/111) with 8% (9/111) confirmed bacterial cultures. The overall serious infection rate was 14% (16/111) with 25% (4/16) confirmed bacterial cultures. Suspected or confirmed infection sites: genitourinary 20% (22/111), pneumonia 5% (7/111), skin/soft tissue 7% (8/111). Noninfectious pneumonitis (NIP) occurred in 5% (5/111). No association regarding the risk of infection between the type of malignancy and ICI used. Steroid use was the only risk factor significantly associated with serious infection: 12/16 (75%) on steroids versus 27/95 (28.4%) without steroid use (p = 0.0003). CONCLUSION: The rate of serious infection with ICI was higher in our study compared with previous reports of pts treated with melanoma. Infectious complications are encountered with ICIs and correlate with steroid use. John Wiley and Sons Inc. 2021-12-07 /pmc/articles/PMC8704147/ /pubmed/34873868 http://dx.doi.org/10.1002/cam4.4393 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Ross, Justine Abella Komoda, Kellie Pal, Sumanta Dickter, Jana Salgia, Ravi Dadwal, Sanjeet Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title | Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title_full | Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title_fullStr | Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title_full_unstemmed | Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title_short | Infectious complications of immune checkpoint inhibitors in solid organ malignancies |
title_sort | infectious complications of immune checkpoint inhibitors in solid organ malignancies |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704147/ https://www.ncbi.nlm.nih.gov/pubmed/34873868 http://dx.doi.org/10.1002/cam4.4393 |
work_keys_str_mv | AT rossjustineabella infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies AT komodakellie infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies AT palsumanta infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies AT dickterjana infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies AT salgiaravi infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies AT dadwalsanjeet infectiouscomplicationsofimmunecheckpointinhibitorsinsolidorganmalignancies |